147 related articles for article (PubMed ID: 24102174)
1. Biological-effect modeling of radioimmunotherapy for non-hodgkins lymphoma: determination of model parameters.
Roberson PL; Wilderman SJ; Avram AM; Kaminski MS; Schipper MJ; Dewaraja YK
Cancer Biother Radiopharm; 2014 Feb; 29(1):26-33. PubMed ID: 24102174
[TBL] [Abstract][Full Text] [Related]
2. Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.
Roberson PL; Amro H; Wilderman SJ; Avram AM; Kaminski MS; Schipper MJ; Dewaraja YK
Eur J Nucl Med Mol Imaging; 2011 May; 38(5):874-83. PubMed ID: 21174088
[TBL] [Abstract][Full Text] [Related]
3. Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.
Koral KF; Dewaraja Y; Li J; Barrett CL; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
J Nucl Med; 2000 Sep; 41(9):1579-86. PubMed ID: 10994741
[TBL] [Abstract][Full Text] [Related]
4. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
[TBL] [Abstract][Full Text] [Related]
5. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
Rajendran JG; Fisher DR; Gopal AK; Durack LD; Press OW; Eary JF
J Nucl Med; 2004 Jun; 45(6):1059-64. PubMed ID: 15181141
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.
Dewaraja YK; Schipper MJ; Shen J; Smith LB; Murgic J; Savas H; Youssef E; Regan D; Wilderman SJ; Roberson PL; Kaminski MS; Avram AM
J Nucl Med; 2014 Jul; 55(7):1047-53. PubMed ID: 24842891
[TBL] [Abstract][Full Text] [Related]
7. Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma.
Roberson PL; Smith LB; Morgan MA; Schipper MJ; Wilderman SJ; Avram AM; Kaminski MS; Dewaraja YK
Cancer Biother Radiopharm; 2017 Nov; 32(9):309-319. PubMed ID: 29083933
[TBL] [Abstract][Full Text] [Related]
8. Prediction of therapy tumor-absorbed dose estimates in I-131 radioimmunotherapy using tracer data via a mixed-model fit to time activity.
Schipper MJ; Koral KF; Avram AM; Kaminski MS; Dewaraja YK
Cancer Biother Radiopharm; 2012 Sep; 27(7):403-11. PubMed ID: 22947086
[TBL] [Abstract][Full Text] [Related]
9. Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood.
Boucek JA; Turner JH
Cancer Biother Radiopharm; 2014 Feb; 29(1):18-25. PubMed ID: 24134141
[TBL] [Abstract][Full Text] [Related]
10. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.
Dewaraja YK; Schipper MJ; Roberson PL; Wilderman SJ; Amro H; Regan DD; Koral KF; Kaminski MS; Avram AM
J Nucl Med; 2010 Jul; 51(7):1155-62. PubMed ID: 20554734
[TBL] [Abstract][Full Text] [Related]
11. Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients.
Koral KF; Dewaraja Y; Li J; Lin Q; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
J Nucl Med; 2003 Mar; 44(3):457-64. PubMed ID: 12621015
[TBL] [Abstract][Full Text] [Related]
12. Comparison of I-131 radioimmunotherapy tumor dosimetry: unit density sphere model versus patient-specific Monte Carlo calculations.
Howard DM; Kearfott KJ; Wilderman SJ; Dewaraja YK
Cancer Biother Radiopharm; 2011 Oct; 26(5):615-21. PubMed ID: 21939358
[TBL] [Abstract][Full Text] [Related]
13. Correlation of tumor radiation-absorbed dose with response is easier to find in previously untreated patients.
Koral KF; Kaminski MS; Wahl RL
J Nucl Med; 2003 Sep; 44(9):1541-3; author reply 1543. PubMed ID: 12960205
[No Abstract] [Full Text] [Related]
14. Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy.
Hartmann Siantar CL; DeNardo GL; DeNardo SJ
J Nucl Med; 2003 Aug; 44(8):1322-9. PubMed ID: 12902424
[TBL] [Abstract][Full Text] [Related]
15. Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report.
Koral KF; Dewaraja Y; Clarke LA; Li J; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
Cancer Biother Radiopharm; 2000 Aug; 15(4):347-55. PubMed ID: 11041019
[TBL] [Abstract][Full Text] [Related]
16. Methodology to incorporate biologically effective dose and equivalent uniform dose in patient-specific 3-dimensional dosimetry for non-Hodgkin lymphoma patients targeted with 131I-tositumomab therapy.
Amro H; Wilderman SJ; Dewaraja YK; Roberson PL
J Nucl Med; 2010 Apr; 51(4):654-9. PubMed ID: 20237032
[TBL] [Abstract][Full Text] [Related]
17. Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study.
Dewaraja YK; Wilderman SJ; Koral KF; Kaminski MS; Avram AM
Cancer Biother Radiopharm; 2009 Aug; 24(4):417-26. PubMed ID: 19694576
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
19. Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphoma.
Hobbs RF; Wahl RL; Frey EC; Kasamon Y; Song H; Huang P; Jones RJ; Sgouros G
J Nucl Med; 2013 Sep; 54(9):1535-42. PubMed ID: 23918734
[TBL] [Abstract][Full Text] [Related]
20. Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.
Rajendran JG; Gopal AK; Fisher DR; Durack LD; Gooley TA; Press OW
J Nucl Med; 2008 May; 49(5):837-44. PubMed ID: 18413376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
